206 related articles for article (PubMed ID: 33202255)
1. A CRISPR-Cas9 repressor for epigenetic silencing of KRAS.
Liu J; Sun M; Cho KB; Gao X; Guo B
Pharmacol Res; 2021 Feb; 164():105304. PubMed ID: 33202255
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting of the oncogenic
Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
[No Abstract] [Full Text] [Related]
3. Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing.
Liu B; Chen S; Rose A; Chen D; Cao F; Zwinderman M; Kiemel D; Aïssi M; Dekker FJ; Haisma HJ
Nucleic Acids Res; 2020 Jan; 48(2):517-532. PubMed ID: 31799598
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells.
Lee W; Lee JH; Jun S; Lee JH; Bang D
Sci Rep; 2018 Aug; 8(1):11879. PubMed ID: 30089886
[TBL] [Abstract][Full Text] [Related]
5. HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer.
Lin CL; Tsai ML; Lin CY; Hsu KW; Hsieh WS; Chi WM; Huang LC; Lee CH
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669676
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-Mediated Knock-Out of Kras
Lentsch E; Li L; Pfeffer S; Ekici AB; Taher L; Pilarsky C; Grützmann R
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739488
[TBL] [Abstract][Full Text] [Related]
7. Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras
McAndrews KM; Xiao F; Chronopoulos A; LeBleu VS; Kugeratski FG; Kalluri R
Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34282051
[TBL] [Abstract][Full Text] [Related]
8. Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing.
Sayed S; Sidorova OA; Hennig A; Augsburg M; Cortés Vesga CP; Abohawya M; Schmitt LT; Sürün D; Stange DE; Mircetic J; Buchholz F
Cancer Res; 2022 Sep; 82(17):3002-3015. PubMed ID: 35802645
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-mediated modification of DNA methylation pattern in the new era of cancer therapy.
Maroufi F; Maali A; Abdollahpour-Alitappeh M; Ahmadi MH; Azad M
Epigenomics; 2020 Oct; 12(20):1845-1859. PubMed ID: 33185489
[TBL] [Abstract][Full Text] [Related]
10. Activation of KRas-ERK1/2 signaling drives the initiation and progression of glioma by suppressing the acetylation of histone H4 at lysine 16.
Wei Y; Wang F; Sang B; Xu Z; Yang D
Life Sci; 2019 May; 225():55-63. PubMed ID: 30946839
[TBL] [Abstract][Full Text] [Related]
11. [Effect of siRNA targeting HDAC1 gene on proliferation, apoptosis, histone acetylation, and histone methylation in gastric cancer cells in vitro].
Zhuang H; Ma X; Lai Y; Xu X; Wang X
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):246-50. PubMed ID: 24589606
[TBL] [Abstract][Full Text] [Related]
12. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
[TBL] [Abstract][Full Text] [Related]
13. A novel cell line generated using the CRISPR/Cas9 technology as universal quality control material for KRAS G12V mutation testing.
Jia S; Zhang R; Lin G; Peng R; Gao P; Han Y; Fu Y; Ding J; Wu Q; Zhang K; Xie J; Li J
J Clin Lab Anal; 2018 Jun; 32(5):e22391. PubMed ID: 29380513
[TBL] [Abstract][Full Text] [Related]
14. Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner.
O'Geen H; Bates SL; Carter SS; Nisson KA; Halmai J; Fink KD; Rhie SK; Farnham PJ; Segal DJ
Epigenetics Chromatin; 2019 May; 12(1):26. PubMed ID: 31053162
[TBL] [Abstract][Full Text] [Related]
15. A review on CRISPR/Cas-based epigenetic regulation in plants.
Jogam P; Sandhya D; Alok A; Peddaboina V; Allini VR; Zhang B
Int J Biol Macromol; 2022 Oct; 219():1261-1271. PubMed ID: 36057300
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas mediated epigenome editing for cancer therapy.
Ansari I; Chaturvedi A; Chitkara D; Singh S
Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/dCas9-Mediated Gene Silencing in Two Plant Fungal Pathogens.
Zhang YM; Zheng L; Xie K
mSphere; 2023 Feb; 8(1):e0059422. PubMed ID: 36655998
[TBL] [Abstract][Full Text] [Related]
19. Exploiting the CRISPR/Cas9 PAM Constraint for Single-Nucleotide Resolution Interventions.
Li Y; Mendiratta S; Ehrhardt K; Kashyap N; White MA; Bleris L
PLoS One; 2016; 11(1):e0144970. PubMed ID: 26788852
[TBL] [Abstract][Full Text] [Related]
20. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
